<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278095</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG0555-CL-103</org_study_id>
    <secondary_id>2010-022457-42</secondary_id>
    <nct_id>NCT01278095</nct_id>
  </id_info>
  <brief_title>Oral Bioavailability of GLPG0555 in Different Solid Formulations</brief_title>
  <official_title>A Randomized, Open Label, 3-way Crossover Study to Compare the Oral Bioavailability of GLPG0555 After Single-dose Intake in Healthy Subjects as a Solid Dispersion Formulation, With and Without Food, Relative to a Nanosuspension Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the pharmacokinetics of a solid capsule formulation of
      GLPG0555 with a nanosuspension, and to assess safety and tolerability of a single dose of
      GLPG0555.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability of solid formulation</measure>
    <time_frame>72 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of single doses of GLPG0555</measure>
    <time_frame>up to 10 days postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG0555 solid dispersion, fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg as solid dispersion capsule, in fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0555 solid dispersion, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg as solid dispersion capsule, after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0555 nanosuspension, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg as nanosuspension, given after breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0555 solid dispersion</intervention_name>
    <description>solid dispersion capsules, 50 mg, single dose</description>
    <arm_group_label>GLPG0555 solid dispersion, fasting</arm_group_label>
    <arm_group_label>GLPG0555 solid dispersion, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0555 nanosuspension</intervention_name>
    <description>Nanosuspension, 50 mg, single dose</description>
    <arm_group_label>GLPG0555 nanosuspension, fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male

          -  BMI between 18-30 kg/mÂ², inclusive.

        Exclusion Criteria:

          -  significantly abnormal platelet function or coagulopathy

          -  smoking

          -  drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerben van 't Klooster, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jos Leempoels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Stuivenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Senior Vice President Development</name_title>
    <organization>Galapagos</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

